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Relationship between methylmalonic acid and cobalamin in suggest that these patients may develop cobalamin defi-
uremia. ciency [4, 5].
Background. To evaluate the requirement for routine sup- The P-cobalamin concentration has been shown toplementation with vitamin B12 and to study the effect of a
have limitations in specificity and sensitivity in diagnos-change from injection to oral B12 supplementation, we exam-
ing B12 deficiency [6–8], and it cannot be expected thatined the relationship between cobalamin and methylmalonic
acid in plasma from 67 patients on chronic hemodialysis, all in the P-cobalamin concentration reflects the relationship
regular therapy with intramuscular cobalamin injections (1 mg) between blood cobalamin and tissue cobalamin accu-
every third month. rately [9–17]. The incidence and prevalence of cobalaminMethods. Starting just before one cobalamin injection, blood
deficiency are unknown in patients with end-stage renalsamples were collected once a month during a nine-month
withdrawal from regular cobalamin substitution to a final three- disease (ESRD). In the older population, the prevalence
month period with cyanocobalamin tablets (1 mg) administered has been reported as high as 11.3 to 14.5% [17, 18].
once daily. Approximately 50% of our patients on chronic hemodi-
Results. Plasma cobalamin was above the lower reference
alysis, similar to the general Danish dialysis population,limit in all subjects, and from a peak value one month after
are more than 60 years old at the start of dialysis [19].the regular injection, the cobalamin concentration during the
withdrawal period decreased to a level below the point of Because of these facts and the recognition of resistance
origin, followed by a significant rise after cyanocobalamin tab- to erythropoietin treatment caused by B12 deficiency [20],
lets. The methylmalonic acid concentrations were above the all patients on chronic hemodialysis in our departmentreference interval. In the withdrawal period, the concentrations
are in a regular, inexpensive, and safe cobalamin substi-significantly increased further, followed by a significant de-
tution with cyanocobalamin injections given every thirdcrease after oral cyanocobalamin substitution.
Conclusion. We demonstrated a within-patient inverse rela- month.
tionship between the concentrations of methylmalonic acid and Methylmalonic acid (MMA) is primarily an intermedi-
cobalamin in plasma from these uremic patients. Despite the ary in the catabolism of isoleucine, valine, odd chainfact that only two of the patients developed subnormal plasma
fatty acids, and cholesterol. Of these, valine is usuallycobalamin values, we demonstrated a B12 depletion during the
reduced and isoleucine normal [21], whereas the lipidswithdrawal period. Treatment with cyanocobalamin tablets
once daily was found efficient, but the oral doses should possi- are often increased in ESRD. Patients with tissue coba-
bly be increased. lamin deficiency have increased concentrations of MMA
in their plasma because 5-deoxyadenosylcobalamin is
required for the enzymatic conversion of l-methylmalo-
Routine supplementation with vitamin B12 (B12) in nyl-CoA to succinyl-CoA by methylmalonyl-CoA mu-
chronic hemodialysis patients is still a matter of debate. tase. As a consequence, the blood level of MMA reflects
Some studies indicate that plasma cobalamins (P-cobal- the cobalamin supply to the tissues. In healthy subjects,
amins) remain normal during dialysis and that generally no increase in P-MMA is seen with age, and no sex-
B12 treatment is not required [1–3], whereas other studies related difference exists. The intake of food has no effect,
and the day-to-day P-MMA variation is negligible [13, 22].
Plasma isoleucine and valine concentrations are largelyKey words: vitamin B12, hemodialysis, kidney failure, plasma cobalam-
ins, erythropoietin treatment. dependent on muscle metabolism, which also determines
the methylmalonyl-CoA production [23]. In healthy hu-Received for publication March 9, 1999
mans, only a tiny fraction of the methylmalonyl-CoAand in revised form July 28, 1999
Accepted for publication August 23, 1999 molecules formed in the mitochondria escapes conver-
sion to succinyl-CoA [24]. Loading with protein and the 2000 by the International Society of Nephrology
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precursors isoleucine and valine in normal subjects re- on regular hemodialysis in our unit. The trial was in
accordance with the Helsinki II declaration, and the pro-sults in a slight, insignificant peak in P-MMA concentra-
tions after two to three hours, but because of further tocol was approved by the regional committee for ethical
evaluation of scientific investigations on human beings.conversion, no significant increase in P-MMA concentra-
tion can be demonstrated five hours after loading [22, 24]. Their ESRD resulted from hereditary (noncystic) kid-
ney diseases (5 patients), cystic- (8 patients), vascular-In contrast with this observation, a significant increase of
an initially elevated P-MMA concentration after isoleu- (9 patients), chronic glomerulonephritis (18 patients),
chronic pyelo-/interstitial nephritis (15 patients), sys-cine loading is a general finding in patients with tissue
cobalamin deficiency [25]. temic diseases (6 patients), and unclassified nondiabetic
nephropathy (6 patients). All patients received individu-Methylmalonic acid is a small (molecular mass 118 g/
mol) and very polar dicarboxylic acid that is not bound ally prescribed dialysis according to urea kinetic model-
ing, and they underwent hemodialysis two or three timesto plasma proteins [26]. In plasma from uremic patients,
a number of organic acids are present at much higher a week, with a duration of three to five hours each time.
Their residual renal function was as follows: daily urineconcentrations than those normally found in healthy sub-
jects, and in a former study, increased concentrations of volume .500 mL (27 patients), daily urine volume ,500
mL (7 patients), and anuria (33 patients). Forty-six pa-five other dicarboxylic acids (adipic, 3-methyladipic, 2,4-
dimethyladipic, pimelic, and azelaic acid) were reported tients were on regular treatment with erythropoietin.
Accesses to hemodialysis were native arteriovenous fis-[27]. However, MMA was not measured.
The development of cobalamin deficiency in the tis- tulae in 46 patients, grafts in 16 patients, and central
venous catheters in 5 patients. In all patients, the bloodsues is considered to be a continuum that lasts for years.
Elevated P-MMA occurs early, and macrocytic anemia flow was $200 mL/min, but none of them were on high-
flux hemodialysis.and/or neurological symptoms occur late in this process
[12, 28–30]. It is now generally accepted that an increased The dialyzers used were Fresenius Hemoflow {F6 (25
patients), F7 (5 patients), and F8 (19 patients); Baxterconcentration of P-MMA strongly suggests cobalamin
CA 170 (6 patients) and Asahi Hollow Fiber Kidneydeficiency, and a diagnostic definition of metabolic co-
[AM-BIO-Wet 65 (5 patients) and 75 (7 patients)]} withbalamin deficiency as an increased concentration of
membranes of polysulfone, cellulose acetate, and Cu-P-MMA that decreases upon injection of cobalamin, has
prammonium rayon. These models have a clearance ofbeen published [13]. However, this definition cannot be
B12 from 59 to 92 mL/min, creatinine clearance from 163used easily in patients with chronic renal insufficiency
to 176 mL/min, urea clearance from 184 to 194 mL/min,or uremia, because MMA, which in normal humans is
and calculated MMA clearance from 86 to 113 mL/min.eliminated by glomerular filtration and passive reabsorp-
From the beginning of hemodialysis treatment, all pa-tion by the tubules [26, 31], in patients with renal insuffi-
tients (hemodialyzed from 0.5 to 22 years, mean 3.7ciency is found in “falsely” high plasma concentrations
years) were on an unrestricted protein diet, and all were[31, 32]. In these patients, a decline after injection with
having regular cobalamin substitution with cyanocobala-cobalamin has not previously been demonstrated [32, 33].
min (1 mg intramuscularly) injections given every thirdMoelby, Rasmussen, and Rasmussen performed the
month. The patients were not routinely administeredfirst study on MMA in chronic hemodialysis patients
other vitamins, but all received iron supplementation[33]. To compare the observations from that study, the
when deemed necessary.aim of this study was to look for any early signs of B12
Blood samples were collected once a month beforedeficiency beyond the formerly described three-month
dialysis from the start of the investigation just beforestudy period (that is, a relationship between MMA and
one cobalamin injection, which was subsequently given.cobalamin in plasma), and to test if oral cobalamin treat-
Hereafter, B12 substitution was interrupted during a nine-ment was as effective in an uremic population as pre-
month withdrawal period, followed by a final three-viously reported in a cobalamin-deficient population
month period employing cyanocobalamin tablets of 1 mg[34]. Therefore, we studied the nondiabetic patients on
administered once daily. Because some patients werechronic hemodialysis in our department during a nine-
dialyzed in the morning and some in the afternoon, wemonth period of withdrawal from regular cobalamin sub-
did not enforce any control of timing of cyanocobalaminstitution followed by a three-month period with cyanoco-
intake versus timing of blood sampling.balamin tablets of 1 mg administered once daily.
Plasma-MMA was determined by a stable-isotope di-
lution technique using solid-phase sample extraction and
METHODS gas chromatography employing a mass spectrometer in
From October 1, 1996, to October 1, 1997, we prospec- the selected ion-monitoring mode [35]. P-cobalamin con-
tively studied all of the 67 nondiabetic patients (42 men centrations were determined with a radioisotope cobal-
amin/folate method from Amersham Internationaland 25 women, aged 25 to 79 years, mean 57 years)
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(Bucks, UK), employing denaturation of endogenous
binding proteins at strongly alkaline pH with purified
hog intrinsic factor as the binding protein [26].
To explore the effect of withdrawal from regular
cobalamin injections on P-MMA, we used Page’s test,
a nonparametric, two-way analysis of variance that is
sensitive to trend and respectful of the repeated-mea-
surement structure of the data. To test the response
of oral cobalamin treatment on P-MMA, the Wilcoxon
signed rank test was used. Serial cobalamin levels were
compared by Page’s test, and to analyze comparisons in
cobalamin concentrations at various time points, both
when cobalamin injections were paused and when oral
cobalamin was instituted, the Wilcoxon signed rank test
was used. To model MMA within-patients during the
withdrawal period as a function of the cobalamin concen-
tration and time, restricted maximal likelihood estima-
tion (REML) was used as implemented in Genstat for
Windows (version 4.1) [36, 37]. This also permitted (in
contrast to the Page’s test) use of all of the data available, Fig. 1. Serial plasma cobalamin levels in 67 patients on chronic hemodi-
alysis during the course of the 12-month study period.including measurements from patients lost during the
course of the study, and patients with unexplained miss-
ing values. This implementation of REML made it possi-
ble to model the variance structure to accommodate the for dropping out. In the following, all registered data
realized within-patient dependencies in the measure- were used.
ments. Furthermore, the expected nonlinear relationship Plasma cobalamin was above the lower reference limit
between B12 and MMA concentrations could be explored (150 pmol/L 5 203 ng/L) in all subjects at start (median
using the facility to include a nonparametric fit of a 499 pmol/L). One month after the initial injection with
smooth curve, a cubic spline [38]. Also, within the frame- cyanocobalamin, the patients had peak values (median
work of REML, it was natural to ascertain the possible 724 pmol/L, 15 values were censored at 1500 pmol/L).
effect of other covariates on MMA. Throughout, diag- Substituting much higher values did not change the con-
nostic plots of residuals guided the modeling and the clusions in the following and after three month with-
models were compared using Wald tests or likelihood drawal from regular B12 injections (just when B12 injec-
ratio tests as appropriate. tion was formerly scheduled), the P-cobalamin returned
to its baseline level (median 501 pmol/L, P 5 0.11).
During withdrawal from three to nine months, the cobal-RESULTS
amin level fell to a level significantly lower than measured
Twenty patients of the 67 participants dropped out at the point of origin (median 392 pmol/L, P , 0.01).
during the study period. The reasons for dropping out After the collection of blood samples at 9 months, all
were accidental cobalamin injection during the with- patients started oral B12 treatment, resulting in a significant
drawal period (1 patient), leaving the county (1 patient), rise in the cobalamin level (median 834 pmol/L, P , 0.01)
transferring from hemodialysis to peritoneal dialysis (5 one month after cyanocobalamin tablets. P-cobalamin
patients), renal transplantation (4 patients), death (5 pa- had a log normal distribution with geometric mean 545
tients caused by myocardial infarction, 2 patients caused pmol/L with 95% confidence interval 218 to 1362 pmol/L
by stroke), and development of a subnormal P-cobal- (Fig. 1 and Table 1). From Figure 1, an exponential
amin level resulting in re-admittance to regular cobal- decline in P-cobalamin concentration seems likely. Mod-
amin therapy (2 patients). These last mentioned patients eling the natural logarithm of B12 as a function of time
had P-MMA values of 1.1 and 0.6 mmol/L, respectively. from time 5 1 to time 5 9 months using REML, we
In 10 of the resulting 47 patients, a few values were found an intercept of 6.49 6 0.0483 (sem) pmol/L and a
assumed to be missing completely at random. Except for slope of 20.05673 6 0.004606 (sem) month21. Hence,
the two patients who developed subnormal P-cobalamin the terminal half-life could be estimated as logn(2)/
values during the study period, the initial B12 injections, (0.05637 6 1.96 3 0.004606), that is, 12.2 months with
withdrawal or oral B12 treatment had no likely influence a 95% confidence interval from 10.5 to 14.5 months. The
intercept (corresponding to a concentration of B12 on 658on the occurrence of missing values or on the reasons
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Table 1. Distribution of cobalamin, MMA, hemoglobin, mean cell volume, albumin, creatinine, and urea in plasma during a 12-month
period in 67 patients on chronic hemodialysis
Time Cob MMA Hb MCV Alb Crea Urea
0.00 490.6 (499.0) 0.7415 (0.660) 6.392 (6.40) 94.03 (95.0) 35.53 (36) 916.5 (891.0) 26.42 (24.90)
1.00 811.7 (724.0) 0.6313 (0.590) 6.485 (6.50) 94.24 (95.0) 35.98 (36) 915.4 (897.0) 25.37 (25.30)
2.00 621.0 (582.5) 0.7084 (0.660) 6.635 (6.55) 94.43 (94.5) 35.15 (35) 863.0 (850.5) 25.36 (23.75)
3.00 543.5 (501.0) 0.7208 (0.680) 6.615 (6.60) 95.14 (96.0) 35.24 (35) 922.3 (878.0) 26.81 (25.30)
4.00 495.2 (464.0) 0.7888 (0.710) 6.707 (6.60) 95.65 (96.0) 36.63 (37) 888.0 (869.0) 27.33 (25.50)
5.00 520.8 (468.0) 0.8940 (0.830) 6.739 (6.60) 96.63 (97.0) 35.84 (35) 896.5 (863.5) 25.98 (25.30)
6.00 481.2 (412.5) 0.8444 (0.780) 6.676 (6.50) 96.35 (97.0) 35.36 (35) 917.2 (896.0) 26.57 (26.50)
7.00 453.5 (401.0) 0.8394 (0.760) 6.694 (6.70) 95.53 (96.0) 36.19 (36) 894.6 (839.0) 25.36 (24.90)
8.00 472.9 (426.0) 0.9151 (0.840) 6.589 (6.60) 94.98 (95.0) 36.38 (37) 851.6 (827.0) 25.58 (25.35)
9.00 452.0 (392.0) 0.9508 (0.860) 6.696 (6.68) 94.66 (95.0) 36.08 (36) 894.6 (861.0) 26.04 (24.80)
10.00 844.5 (834.0) 0.7338 (0.715) 6.650 (6.80) 93.15 (93.0) 35.94 (36) 900.9 (866.0) 25.38 (25.65)
11.00 882.9 (861.0) 0.7185 (0.690) 6.535 (6.60) 93.78 (93.0) 36.67 (37) 876.0 (855.0) 25.75 (24.55)
12.00 877.6 (857.0) 0.7885 (0.735) 6.646 (6.70) 93.35 (93.0) 35.48 (36) 895.1 (858.0) 25.16 (26.15)
Data are mean (median) values. Abbreviations are: Cob, cobalamin (normal range 150–600 pmol/L); MMA, methylmalonic acid (normal range 0.08–0.28 mmol/L);
Hb, hemoglobin (normal range for males 8.3–10.7 mmol/L, and females 7.5–9.4 mmol/L); MCV, mean cell volume (normal range 85–100 fL); Alb, albumin (normal
range ,50 year, 40–51 g/L, and .50 year, 37–48 g/L); Crea, creatinine (normal range for males, 60–125 mmol/L and females, 55–115 mmol/L); Urea (normal range
3.0–7.5 mmol/L).
pmol/L) was lower than the geometric mean observed at
one month (745 pmol), indicating that the procedure lost
an early phase of distribution. This is not unlikely given
that no earlier measurements were present. Hence, to
assess the volume of distribution of B12, we used the
geometric means of B12 at time 5 0 (461 pmol/L) and
time 5 1 (745 pmol/L). Because the molecular weight
of B12 is 1355, an approximate assessment of the volume
of distribution can be obtained as (738,000 pmol)/(745 2
461) pmol/L , 2600 L following injection of 1 mg coba-
lamin. This is bound to be an overestimation to the extent
that the measurement at one month underestimates the
peak value of B12.
The concentrations of P-MMA were originally above
the central 95th percentile reference interval of healthy
subjects (Table 1) [39] in all patients, median 0.66
mmol/L. The MMA values had declined one month after
the cobalamin injections (median 0.59 mmol/L). During
the rest of the withdrawal period, the P-MMA concentra-
tions increased further to a maximum at the time 5 9
Fig. 2. Serial plasma methylmalonic acid (MMA) values in 67 uremicmonths (median 0.86 mmol/L, P , 0.05), followed by a patients during the course of the 12-month study period.
significant decrease after oral B12 substitution (P , 0.01).
MMA had a log normal distribution with geometric
mean of 0.730 and a 95% confidence interval from 0.344
of 0.988 was obtained. Incorporating the other registeredto 1.595 mmol/L (Fig. 2 and Table 1).
variables as fixed factors showed them to be of no sig-Using REML to analyze the mixed model, a simple
nificant importance to the MMA response. Because themodel employing “time” and “B12” as fixed parameters
primary objective of this modeling was to understandand patient identity as random factors fitted the data
the relationship between MMA and B12, we elected not towell and showed a very significant inverse relationship
include the measurements while on oral cyanocobalaminbetween MMA and B12 (P , 0.005). The final model
treatment. As explained in the Methods section, the in-included an autoregressive error structure (correlation
take of cyanocobalamin tablets was not standardizedcoefficient between one MMA and the next within-pa-
versus the blood sampling. We may therefore have over-tient of 0.914 6 0.02) and a nonlinear effect (cubic spline)
estimated some B12 values in that part of the study (evenof B12 and time (both P , 0.05; Fig. 3). Finally, allowance
if the parameters of the final model was almost identical,was made for inconstant variance at different points in
time. A correlation between measured and fitted MMA whether the later points are included or not).
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Fig. 3. Common spline with vitamin B12. Fig. 4. Relationship between MMA and cobalamin in the study popu-
lation.
All the patients were anemic with mean cell volumes
this conclusion, and to demonstrate the potential impor-in the reference interval during the examination period.
tance of an increased MMA level in uremic patients.Their serum albumin levels were slightly under the lower
Using within-patient comparisons, we have found thatreference limit in our laboratory (mean value of 36 g/L),
even if MMA values were high, they responded quicklybut all had an approximately normalized protein cata-
to changes in B12 concentrations. This was evident bothbolic rate of 1.0. The mean predialysis concentrations of
from the response to the last injection given at time 5creatinine and urea in serum were 895 mmol/L and 26
0 and when oral treatment was started nine months latermmol/L, respectively (Table 1).
(Fig. 2). Furthermore, the inverse relationship was found
to reach an asymptote at B12 levels above 700 pmol/L,
DISCUSSION as indicated by the plot of geometric means and 95%
Some years ago, we reported that linear relationships percentiles of MMA versus B12 (Fig. 4) and by the spline
exist between the concentrations of MMA in serum and (Fig. 3). From a physiological point of view, this might
urine in clinical cobalamin-deficient patients and that be reasonable because it indicates that at some level of
B12, even ESRD patients may have enough, and hence,these patients have a negative correlation between cobal-
amin and MMA in serum [26]. We have also shown that no further decrease in MMA will occur. However, the
observation that MMA is responsive to B12 concentra-the serum MMA assay discriminates between clinically
confirmed cobalamin deficiency and noncobalamin defi- tions up to about 700 pmol/L indicates that if B12-respon-
sive MMA can indeed be taken as evidence for metabolicciency [7]. Because of impaired renal excretion, the
P-MMA concentrations are elevated in noncobalamin- cobalamin deficiency, a much higher P-cobalamin con-
centration is required in uremia, at least under the cir-deficient patients with decreased glomerular filtration
rates [31, 32] and in uremic patients on chronic hemodial- cumstances of our study. If this result is confirmed, fur-
ther studies will show whether this phenomenon isysis [33]. In the last mentioned cross-sectional study, we
found no significant correlation between concentrations caused by tissue resistance toward cobalamin or related
to the fact that P-cobalamins are a poor estimate of theof cobalamin and MMA, MMA and creatinine or cobal-
amin and creatinine in serum. We concluded that an total amount of B12 available for the tissues.
It is essential that the conclusions from the Page’s testsincreased concentration of MMA in plasma is a general
finding in non–cobalamin-deficient, uremic patients and and the Wilcoxon tests are fully supported by the results
from the comprehensive mixed model. Only the latterthat the MMA assay is useless to establish a diagnosis
of cobalamin deficiency in uremic patients. The design takes full account of the entire set of data and therefore
obviates any speculation that the results might whollyof the actual study has made it possible to reconsider
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or partly be explained by bias caused by the number of these proportions change in uremia or are secondary to
the changing availability of cobalamin is not known. Thedropouts.
Even if B12 was an important determinant of MMA, high degree of protein binding of B12 ensures that very
little B12 is available for dialysis.in our study, it is necessary to add that changes in B12
did not explain all of the variation in MMA. To get the Similar to the observations from a study on high-flux
hemodialysis patients [4], we have found a significantbest prediction (r 5 0.988) of MMA, it was necessary to
have “time” in the model. This means that during the fall in the B12 level (with a half-life of approximately 12
months) over the nine-month withdrawal period. Duringwithdrawal period, MMA increases beyond what can be
explained by the decrease in B12 and hence weakens the this time, two patients developed subnormal B12 values.
Our dialyzers had a B12 clearance between 59 and 92implication of a high MMA as a mark of B12 deficiency.
A possible reason for the elevated MMA values not mL/min. With the calculated volume of distribution of
2600 L (discussed in the Results section), we can estimateexplained by B12 could be that the metabolic pathways
involving MMA were stressed by increased substrate. a time constant, k, of (59 or 35 mL/min)/2,600,000 5
2.3 3 1025 min21 or 3.5 3 1025 min21. Allowing for fourFor instance, increased production of propionic acid
from bacterial overgrowth in the small intestine [40] or hours of dialysis, three times a week, and considering
that the two-pool nature of B12 kinetics approximatelyincreased catabolism of MMA-precursors like choles-
terol and odd chain fatty acids may increase MMA. halves the dialysis removal compared with a single-pool
model [46], the half-life is found as (2 3 logn(2)/k)/Finally, a discordant relationship between MMA and
cobalamin could be predicted on the basis that the major- 0.07 , 13 months or 20 months. Thus, from these data,
it appears that dialysis alone might explain most of theity of the cobalamins as measured in plasma is bound to
haptocorrin (TC I) with a half-life between six and nine decline in B12 observed during withdrawal from B12 injec-
tions.days. The function of this transport mechanism is un-
known, and the cobalamins bound to TC I are not consid- A loss of cobalamin from the body has been reported
to occur at a rate of approximately 0.1% per day, corre-ered available for the tissues. In contrast, transcobalamin
II (TC II) with a much shorter half-life transports B12 to sponding to a half-life of approximately 23 months [47],
and other estimates have found a half-life of approxi-the tissues. Hence, if B12 partitioned differently between
TC I and TC II, a different relationship between the mately one year [48]. The results therefore indicate that
during withdrawal from cobalamin injections, dialysiscobalamins as measured and MMA might occur. It is
possible that direct measurement of the B12-TC II com- eliminated an amount similar to the dietary intake of B12.
The recommended dietary allowances of B12 are 2 mg/plex could solve this issue [41]; however, the specificity
of this test needs clarification [42], and it has not yet day [49]. A reduced intake of B12 by itself should not
lead to cobalamin deficiency in the presence of normalbeen applied in uremic patients. A single study has found
total TC II normal in patients with chronic renal failure stores [50]. Our patients have traditionally been allowed
a liberal diet in proteins, so even if we cannot exclude[43].
To strengthen our interpretation that the decreasing that dietary factors could contribute to the declining B12
during withdrawal, we find it unlikely that malnutritionMMA upon B12 administration reflects metabolic cobal-
amin deficiency, it might have been interesting if we had could play a major role. In a recently reported study, it
was concluded that the high frequency of mildly abnor-determined homocysteine values and seen them follow
MMA as B12 changed. Very recently, 14 patients on he- mal cobalamin status in the older population could not
be attributed to a poor intake of cobalamin. Instead,modialysis selected for a low B12 (,180 pmol/L) were
shown to respond to intense B12 treatment with a de- nondietary reasons, such as malabsorption, must be
sought [50], but malabsorption has not been describedcrease in MMA on average by 48%, which correlated
with a decrease in homocysteine. Differences from this in uremic patients. In a previous study [45], both malnu-
trition and malabsorption were excluded as likely rea-study include that the patients were selected and there-
fore had a lower B12 than ours, and their dose of B12 was sons for low B12 values in patients on maintenance hemo-
dialysis. Whether phosphate binders reduce absorptionmuch higher [44]. Some clinical evidence that a higher
than usual B12 level may be necessary in uremic patients of cobalamin has not, to our knowledge, been studied.
Hence, we believe that elimination of B12 during dial-has been obtained [45].
It has been debated for years whether or not the rou- ysis is a possible mechanism to explain the declining
concentration observed from time 5 1 to time 5 9tine administration of cobalamin is necessary for patients
on maintenance hemodialysis. As mentioned, the cobal- months (Fig. 1). Our analysis does not exclude the possi-
bility that regular administration of B12 leading to rela-amins in plasma are attached to TC I and TC II. TC I
carries two thirds of the P-cobalamins, and one third are tively high concentrations and possibly a higher than
normal unbound fraction of B12 could directly increaseattached to TC II, the protein that carries cobalamin
from the intestine to the cells of the body [13]. Whether the elimination during dialysis. If that was the case, with-
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drawal of B12 beyond the nine-month period used here more, a recent study on 38 patients with newly diagnosed
cobalamin deficiency found that 2 mg B12 orally dailymight not lead to a further decline in B12 concentration,
and no genuine cobalamin deficiency would develop. was possibly even superior to 1 mg intramuscularly on
a monthly basis [34]. These patients were not on hemodi-Our results that MMA is sensitive to B12 up to a concen-
tration of 700 pmol/L is, however, at variance with this alysis, however.
Apart from convenience and the higher price for theexplanation. We find it more natural to assume that
negative B12 balance is a continuum, resulting in develop- oral administration (approximately $20 for oral versus
$8 for intramuscular treatment on a three month basis inment of cobalamin deficiency [28], although only two of
our patients developed P-cobalamin values below 220 Denmark), future studies must show whether the cyanide
load provided by cyanocobalamin is of clinical impor-pmol/L [51].
Recently, it has been demonstrated that elevated tance [55].
In conclusion, a reasonable explanation for the de-homocysteine levels are related to increased cardiovas-
cular morbidity in the population at large and in patients creasing P-cobalamin level during the withdrawal period
could be negative B12 balance or depletion caused byon dialysis. At least some of this increase in homocys-
teine can be curtailed by the administration of folic acid. dialysis. It is likely that such an effect would increase
when dialysis providing higher clearance of middle mole-This has led to the recommendation that 5 to 15 mg folic
acid should be given daily to patients on dialysis [52]. It cules is used. Similarly, further studies will look at this
problem in patients on peritoneal dialysis.has been acknowledged that the administration of folic
acid to B12-deficient patients might either mask the hema- We demonstrate an inverse relationship between the
concentrations of MMA and cobalamin in plasma fromtological signs of cobalamin deficiency or perhaps even
precipitate neurological deterioration. It is possible that these patients at a level of P-cobalamin in which defi-
ciency would otherwise have been thought unlikely. Asuremic patients could be even more sensitive to this
effect because of the decreased concentration of methio- measured by the response in P-cobalamin and P-MMA,
we found that treatment with cyanocobalamin tabletsnine [53]. It is therefore vital before giving folic acid to
be able to exclude B12 deficiency. If a B12-responsive once daily was efficient. Our findings may support the
use of the MMA assay in diagnosing of cobalamin defi-increased MMA concentration is indeed reflective of B12
deficiency, our results indicate that most, if not all, folic ciency in ESRD patients. Further work is necessary to
define a possibly dynamic reference interval of MMA inacid treatment in uremic patients should be accompanied
by B12. In fact, the only controlled study to prove the plasma from uremic patients.
effect of folic acid in reducing homocysteine in dialysis
patients did include 1 mg B12 with 15 mg folic acid [54], ACKNOWLEDGMENTS
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